<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02194257</url>
  </required_header>
  <id_info>
    <org_study_id>18.494</org_study_id>
    <nct_id>NCT02194257</nct_id>
  </id_info>
  <brief_title>Investigation of the Metabolism and Pharmacokinetics of Ambroxol in Healthy Male Volunteers</brief_title>
  <official_title>Investigation of the Metabolism and Pharmacokinetics of an Open Label Single Dose of 20 mg Ambroxol Administered as a Lozenge Together With an Oral Solution of 0.4 mg [14C]-Ambroxol in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to determine the basic pharmacokinetics of ambroxol and [14C]-radioactivity including
      mass balance, excretion pathways and complete metabolism in healthy male volunteers following
      administration of a lozenge of 20 mg ambroxol together with an oral solution of 0.4 mg
      [14C]-ambroxol labelled in two different positions
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Individual time course profiles of [14C]-radioactivity (in nmoleq/L or nmoleq/kg for faeces) in plasma</measure>
    <time_frame>up to 120 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Individual time course profiles of ambroxol in plasma</measure>
    <time_frame>up to 120 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate and extent of excretion mass balance based on the total radioactivity in urine and faeces</measure>
    <time_frame>up to 216 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Identification of major metabolites in urine, feces and plasma in comparison with various animal species</measure>
    <time_frame>up to 48 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cblood cells/Cplasma ratio of [14C]-radioactivity and Cblood /Cplasma ratio of [14C]-radioactivity</measure>
    <time_frame>up to 120 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (maximum concentration of the analyte(s) in plasma)</measure>
    <time_frame>up to 120 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>tmax (time from dosing to the maximum concentration of the analyte(s) in plasma)</measure>
    <time_frame>up to 120 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-tz (area under the concentration-time curve of the analyte(s) in plasma over the time interval from 0 to the time of the last quantifiable data point)</measure>
    <time_frame>up to 120 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-∞ (area under the concentration-time curve of the analyte(s) in plasma over the time interval from 0 to infinity)</measure>
    <time_frame>up to 120 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>λz (terminal rate constant in plasma)</measure>
    <time_frame>up to 120 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2 (terminal half-life of the analyte(s) in plasma)</measure>
    <time_frame>up to 120 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>MRTpo (mean residence time of the analyte(s) in the body after oral administration)</measure>
    <time_frame>up to 120 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CL/F (total clearance of the analyte in plasma after oral administration)</measure>
    <time_frame>up to 120 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vz/F (apparent volume of distribution during the terminal phase λz following an oral dose)</measure>
    <time_frame>up to 120 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ae0-tz (amount of analyte that is eliminated in urine within the time interval zero to tz)</measure>
    <time_frame>up to 216 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Aefaeces,0-tz (amount of analyte excreted in faeces within the time interval zero to tz)</measure>
    <time_frame>up to 216 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>fefaeces,0-tz (fraction of analyte excreted in faeces within the time interval zero to tz in % of dose)</measure>
    <time_frame>up to 216 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CLR,t1-t2 (renal clearance of analyte from the within the time interval t1 to t2)</measure>
    <time_frame>up to 216 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>fe0-tz (fraction of analyte excreted in urine within the time interval zero to tz in % of dose)</measure>
    <time_frame>up to 216 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Individual time course profiles of [14C]-radioactivity (in nmoleq/L or nmoleq/kg for faeces) in urine</measure>
    <time_frame>up to 216 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Individual time course profiles of [14C]-radioactivity (in nmoleq/L or nmoleq/kg for faeces) in faeces</measure>
    <time_frame>up to 216 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Individual time course profiles of ambroxol in urine</measure>
    <time_frame>up to 216 hours after drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinically significant changes vital signs (blood pressure [BP], pulse rate [PR])</measure>
    <time_frame>up to 39 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>up to 39 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinically significant changes in 12-lead electrocardiogram (ECG)</measure>
    <time_frame>up to 39 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with abnormal changes in laboratory parameters</measure>
    <time_frame>up to 39 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of tolerability on a 4-point scale</measure>
    <time_frame>Day 14</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>[14C]-cyclohexane ambroxol oral solution + ambroxol lozenge</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>[14C]-benzyl ambroxol oral solution + ambroxol lozenge</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C]-cyclohexane ambroxol oral solution</intervention_name>
    <arm_group_label>[14C]-cyclohexane ambroxol oral solution + ambroxol lozenge</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C]-benzyl ambroxol oral solution</intervention_name>
    <arm_group_label>[14C]-benzyl ambroxol oral solution + ambroxol lozenge</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ambroxol lozenge</intervention_name>
    <arm_group_label>[14C]-cyclohexane ambroxol oral solution + ambroxol lozenge</arm_group_label>
    <arm_group_label>[14C]-benzyl ambroxol oral solution + ambroxol lozenge</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males according to the following criteria: Based upon a complete medical
             history, including the physical examination, vital signs (Blood Pressure (BP), Pulse
             Rate (PR)), 12-lead Electrocardiogram (ECG), clinical laboratory tests

          -  Age ≥18 and ≤65 years

          -  Body mass index (BMI) ≥18.5 and BMI ≤29.9 kg/m2

          -  Signed and dated written informed consent prior to admission to the study in
             accordance with Good Clinical Practice (GCP) and the local legislation

        Exclusion Criteria:

          -  Any finding of the medical examination (including BP, PR and ECG) deviating from
             normal and of clinical relevance

          -  Any evidence of a clinically relevant concomitant disease

          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders

          -  Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or
             neurological disorders

          -  History of relevant orthostatic hypotension, fainting spells or blackouts

          -  Chronic or relevant acute infections

          -  History of relevant allergy/hypersensitivity (including allergy to study drug or its
             excipients)

          -  Intake of drugs with a long half-life (&gt; 24 hours) within at least one month or less
             than ten half-lives of the respective drug prior to administration or during the trial

          -  Use of drugs which might reasonably influence the results of the trial based on the
             knowledge at the time of protocol preparation within ten days prior to administration
             until after the last sample from Visit 2 is collected

          -  Participation in another trial with an investigational drug within two months prior to
             administration or during the trial

          -  Smoker (&gt; 10 cigarettes or &gt; 3 cigars or &gt; 3 pipes/day)

          -  Inability to refrain from smoking during the stay in the trial centre

          -  Alcohol abuse (more than on average two units of alcoholic beverages per day or more
             than 14 units per week (one unit equals one pint [285 mL] of beer or lager, one glass
             [125 mL] of wine, 25 mL shot of 40% spirit)).

          -  Drug abuse

          -  Blood donation (more than 100 mL within 60 days prior to study drug administration or
             during the trial)

          -  Excessive physical activities (within one week prior to administration or during the
             Trial until follow-up examination)

          -  Any laboratory value outside the reference range that is of clinical relevance

          -  Inability to comply with dietary regimen of study centre

          -  A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a
             QTc interval &gt;450 ms)

        Exclusion criteria specific for this study:

          -  Veins unsuitable for blood sampling

          -  PR interval &gt;220 ms or QRS interval &gt;120 ms

          -  Exposure to radiation for diagnostic reasons (except dental X-rays and plain X-rays of
             thorax and bony skeleton [excluding spinal column]), during work or during
             participation in a medical trial in the previous year

          -  Irregular defecation pattern (less than once per two days)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 17, 2014</study_first_submitted>
  <study_first_submitted_qc>July 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2014</study_first_posted>
  <last_update_submitted>July 17, 2014</last_update_submitted>
  <last_update_submitted_qc>July 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ambroxol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

